Tone mix
Week by week 52 weeks
Share of Vivos Therapeutics, Inc. Common Stock's 117 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Feb 24, 2025 · tone +100Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic alliance+80
- Week of Jan 13, 2025 · tone 0Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Down 21.5% in December-76
- Week of Jun 1, 2026 · tone +97Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing+74
- Week of Oct 12, 2026 · tone +99Vivos Therapeutics Strikes $12M Stock Deal For SOD Sciences Stake And Test Rights+65
- Week of Oct 28, 2024 · tone 0Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Declines By 25.4%-60
- Week of Jan 20, 2025 · tone 0Analyzing Sensus Healthcare (NASDAQ:SRTS) and Vivos Therapeutics (NASDAQ:VVOS)-59
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Vivos Therapeutics, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 3 | +89 |
| Last 30 sessions | 13 | +77 |
| Last 90 sessions | 31 | +55 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, October 30, 2026
3 headlines, average tone +89: 3 positive, 0 neutral and 0 negative. Showing all 3.
- www.californiatelegraph.com · 5 outletsCORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell TestPositive
- www.finanznachrichten.de · 1 outletSOD SCIENCES INC.: CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell TestPositive
- www.pr-inside.com · 1 outletCORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor ...Positive
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test | www.californiatelegraph.com | 5 | Positive |
| SOD SCIENCES INC.: CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test | www.finanznachrichten.de | 1 | Positive |
| CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor ... | www.pr-inside.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletVivos Therapeutics (Nasdaq: VVOS) regains Nasdaq compliance after SOD dealPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Vivos Therapeutics (Nasdaq: VVOS) regains Nasdaq compliance after SOD deal | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
4 headlines, average tone +90: 4 positive, 0 neutral and 0 negative. Showing all 4.
- www.hawaiitelegraph.com · 2 outletsSOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell TestPositive
- www.manilatimes.net · 1 outletVivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity StandardPositive
- www.finanznachrichten.de · 1 outletSOD SCIENCES INC.: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell TestPositive
- www.pr-inside.com · 1 outletSOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and ...Positive
Show the table · 4 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test | www.hawaiitelegraph.com | 2 | Positive |
| Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard | www.manilatimes.net | 1 | Positive |
| SOD SCIENCES INC.: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test | www.finanznachrichten.de | 1 | Positive |
| SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and ... | www.pr-inside.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 16, 2026
2 headlines, average tone +99: 2 positive, 0 neutral and 0 negative. Showing all 2.
- www.rttnews.com · 1 outletVivos Therapeutics Strikes $12M Stock Deal For SOD Sciences Stake And Test RightsPositive
- www.manilatimes.net · 1 outletVivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia TestPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Vivos Therapeutics Strikes $12M Stock Deal For SOD Sciences Stake And Test Rights | www.rttnews.com | 1 | Positive |
| Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test | www.manilatimes.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 2, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletVivos Therapeutics (NASDAQ:VVOS) versus Venus Concept (NASDAQ:VERO) Financial ReviewNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Vivos Therapeutics (NASDAQ:VVOS) versus Venus Concept (NASDAQ:VERO) Financial Review | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Vivos Therapeutics, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.